Author response for 'Efficacy and safety of enavogliflozin, a novel <scp>SGLT2</scp> inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> trial'

Authors :: null Soo Heon Kwak
null Kyung Ah Han
null Kyung‐Soo Kim
null Jae Myung Yu
null EunSook Kim
null Jong Chul Won
null Jun Goo Kang
null Choon Hee Chung
null Seungjoon Oh
null Sung Hee Choi
null Kyu Chang Won
null Sin Gon Kim
null Seung Ah Cho
null Bo Young Cho
null Kyong Soo Park
Publication Year :: 2023
Publisher :: Wiley, 2023.

Tools